The efficacy and safety of chemoimmunotherapy in patients with MSI-L/MSS/pMMR status metastatic colorectal cancer: a systematic review and meta-analysis of randomized controlled trials.

Front Oncol · 2025 · PMC12197930 · PMID 40575168

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For example, combining PD-1/PD-L1 antibodies with regorafenib: in the REGOMUNE study, combining regorafenib with avelumab for the treatment of MSS CRC patients demonstrated that this combination therapy can enhance anti-tumor immunity; in the REGOTORI study, the combination of regorafenib with toripalimab for the treatment of MSS mCRC showed efficacy but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.